Immunogenetics and infectious diseases: Special reference to the mayor histocompatibility complex

Brazilian Journal of Infectious Diseases

Volumn 10, Issue 2, 2006, Pages 122-131

  Alves, Crésio ^a,b   Souza, Thaisa ^a   Meyer, Isadora ^a   Toralles, Maria Betânia P ^a   Brites, Carlos ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b NONE   (Brazil)

Author keywords

HLA; Infectious diseases; Major histocompatibility complex

Indexed keywords

ANTIRETROVIRUS AGENT; HLA ANTIGEN; T LYMPHOCYTE RECEPTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIGEN DETECTION; BACTERIAL INFECTION; BACTERIAL STRAIN; CELLULAR IMMUNITY; CHAGAS DISEASE; CLINICAL FEATURE; CORRELATION ANALYSIS; DENGUE; DISEASE SEVERITY; GENE FREQUENCY; GENE IDENTIFICATION; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC CODE; GENETIC MARKER; GENETIC RISK; HEPATITIS B; HEPATITIS C; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HLA SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS INFECTION; IMMUNOGENETICS; IMMUNOSTIMULATION; INFECTION RISK; INFECTION SENSITIVITY; LEPROSY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALARIA; MYCOSIS; NOMENCLATURE; NONHUMAN; PARASITE; PARASITOSIS; PATHOGENESIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCHISTOSOMIASIS; SKIN LEISHMANIASIS; T LYMPHOCYTE ACTIVATION; TUBERCULOSIS; VIRUS INFECTION; VIRUS LOAD; VIRUS STRAIN; VISCERAL LEISHMANIASIS;

EID: 33746897017     PISSN: 14138670     EISSN: 14138670     Source Type: Journal    
DOI: 10.1590/S1413-86702006000200010     Document Type: Review

References (111)

1. Furusho J.K.Y. Papel de los genes del complexo principal de histocompatibilidad en los processos infecciosos. Rev Invest Clin 2000;52(4):461-6.
2. Fernandes A., Maciel L., Foss M., Donadi E.A. Como entender a associação entre o sistema HLA e as doenças auto-imunes endócrinas. Arq Bras Endocrinol Metab 2003; 47(5):601-11.
3. Klein J., Sato A. The HLA Sistem - First of two parts. N Engl J Med 2000;343(11):702-9.
4. Van Rood J.J. The impact of the HLA-system in clinical medicine. Shweiz Med Wschr 1993;123:85-92.
5. Singh N., Agrawal S., Rastogi A.K. Infectious diseases and immunity: special reference to major histocompatibility complex. Emerg Infect Dis 1997;3(1):41-9.
6. Donadi E. A. Como entender a nomenclatura e os mecanismos de associação entre os antígenos e os alelos de histocompatibilidade com as doenças. Medicina (Ribeirão Preto) 2000;33:7-18.
7. Terasaki P.I., McClelland J.D. Microdroplet assay of human serum cytotoxins. Nature 1964;204:998-1000.
8. Marsh S.G.E., Ekkehard A.D., Bodmer W.F. et al. Nomenclature for factors of the HLA system. Tissue Antigens 2002;60:407-64.
9. Hill A.V. The immunogenetics of human infectious diseases. Annu Rev Immunol. 1998;16:593-617.
10. Marcos E.V.C., Souza F.C., Ura S., Opromolla D.V.A. Estudo de associação entre antígenos HLA e reação hansênica tipo 1 ulcerada. An Bras Dermatol 2000;75(3):283-90.
11. Klein J., Sato A. The HLA System: Second of Two Parts. N Engl J Med 2000;343(11):782-6.
12. Mack D.G., Johnson J.J., Roberts F., et al. HLA-class II genes modify outcome of Toxoplasma gondii infection. Int J Parasitol 1999;29:1351-8.
13. Carrington M., Nelson G.W, Martin M.P., et al. HLA and HIV-1: Heterozygote advantage and B*35-Cw*04 disadvantage. Science 1999;283:1748-52.
14. Rajalingam R., Mehra N.K., Jain R.C., et al. Polymerase chain reaction-based sequence-specific oligonucleotide hybridization analysis of HLA class II antigens in pulmonary tuberculosis: relevance to chemotherapy and disease severity. J Infect Dis 1996;173:6.
15. Amirzargar A.A., Yalda A., Hajabolbaghi M., et al. The association of HLA-DRB, DQA1, DQB1 alleles and haplotype frequency in Iranian patients with pulmonary tuberculosis. Int J Tuberc Lung Dis 2004;8(8):1017-21.
16. Selvaraj P., Reetha A.M., Uma H., et al. Influence of HLA-DR and -DO phenotypes on tuberculin reactive status in pulmonary tuberculosis patients. Tuber Lung Dis 1996;77(4):369-73.
17. Ravikumar M., Dheenadhayalan V., Rajaram K., et al. Associations of HLA-DRB1, DQB1 and DPB1 alleles with pulmonary tuberculosis in south India. Tuber Lung Dis 1999;79(5):309-17.
18. Mehra N.K., Rajalingam R., Mitra D.K., et al. Variants of HLA-DR2/DR51 group haplotypes and susceptibility to tuberculoid leprosy and pulmonary tuberculosis in Asian Indians. Int J Lepr Other Mycobact Dis 1995;63(2):241-8.
19. Dubaniewicz A. HLA-DR antigens in patients with pulmonary tuberculosis in northern Poland: Preliminary report. Arch Immunol Ther Exp (Warsz) 2000;48(1):47-50.
20. Brahmajothi V., Pitchappan R.M., Kakkanaiah V.N., et al. Association of pulmonary tuberculosis and HLA in South India. Tubercle 1991;72(2):123-32.
21. Sanjeevi C.B., Narayanan P.R., Prabakar R., et al. No association or linkage with HLA-DR or -DQ genes in south Indians with pulmonary tuberculosis. Tuber Lung Dis 1992;73(5):280-4.
22. Shankarkumar U. HLA associations in leprosy patients from Mumbai, India. Lepr Rev 2004;75(1):79-85.
23. Mehra N.K., Rajalingam R., Mitra D.K., et al. Variants of HLA-DR2/DR51 group haplotypes and susceptibility to tuberculoid leprosy and pulmonary tuberculosis in Asian Indians. Int J Lepr Other Mycobact Dis. 1995;63(2):241-8.
24. Gorodezky C., Alaez C., Munguia A., et al. Molecular mechanisms of MHC linked susceptibility in leprosy: towards the development of synthetic vaccines. Tuberculosis (Edinb) 2004;84(1-2):82-92.
25. Rani R., Ferandez-Vina M.A., Zaheer S.A., et al. Study of HLA class II alleles by PCR oligo-typing in leprosy patients from North India. Tissue Antigens 1993;42:133-7.
26. Miller E.N., Jamieson S.E., Joberty C., et al. Genome-wide scans for leprosy and tuberculosis susceptibility genes in Brazilians. Genes Immu 2004;5(1):63-7.
27. Visentainer J.E., Tsuneto L.T., Serra M.F., et al. Association of leprosy with HLA-DR2 in a Southern Brazilian population. Braz J Med Biol Res 1997;30(1):51-9.
28. Wakefield D., Montanaro A., McCluskey P. Acute anterior uveitis and HLA-B27. Surv Ophtalmol 1991;36:223-32.
29. Scofield R.H., Kurien B., Gross T., et al. HLA-B27 binding of peptide from its own sequence and similar peptides from bacteria: implications for spondyloarthropathies. Lancet 1995;345:1542-4.
30. Feldtkeller E., Khan M.A., van der Heijde D., et al. Age at disease onset and diagnosis delay in HLA-B27 negative versus positive patients with ankylosing spondylitis. Rheumatol Int 2003;23(2):61-6.
31. Smith J.R. HLA-B27-associated uveitis. Ophthalmol Clin North Am 2002;15(3):297-307.
32. Kerkhoff F.T., Rothova A. Bartonella henselae associated uveitis and HLA-B27. J Ophthalmol 2000;84(10):1125-9.
33. Heiligenhaus A., Rebmann V., Neubert A., et al. Soluble HLA class I and HLA-DR plasma levels in patients with anterior uveitis. Tissue Antigens 2004;63(4):369-75.
34. Tarasova L.N., Drozdova E.A. Clinical features of HLA-B27 positive and negative uveitis. Vestn Oftalmol 2000;116(3):25-7.
35. Shimamoto Y., Sugiyama H., Hirohata S. Reiter's syndrome associated with HLA-B51. Intern Med 2000;39 (2):182-4.
36. Taniguchi Y., Yorioka N., Kyuden Y., Asakimori Y. Reiter's syndrome associated with HLA-B51: a case report. J Int Med Res 2003;31(1):55-7.
37. Monnet D., Breban M., Hudry C., et al. Ophthalmic findings and frequency of extraocular manifestations in patients with HLA-B27 uveitis: a study of 175 cases. Ophthalmology 2004;111(4):802-9.
38. Fernandez-Melon J., Munoz-Fernandez S., Hidalgo V., et al. Uveitis as the initial clinical manifestation in patients with spondyloarthropathies. J Rheumatol 2004;31(3):524-7.
39. Queiro R., Torre J.C., Belzunegui J., et al. Clinical features and predictive factors in psoriatic arthritis-related uveitis. Semin Arthritis Rheum 2002;31(4):264-70.
40. Hananantachai H., Patarapotikul J., Ohashi J., et al. Polymorphisms of the HLA-B and HLA-DRB1 Genes in Thai Malaria Patients. Jpn J Infect Dis 2005;58(1):25-8.
41. Hill A.V.S., Elvin J., Willis A.C., et al. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature 1992;360:434-9.
42. Shankarkumar U., Devaraj J.P., Ghosh K., et al. HLA associations in P. falciparum malaria patients from Mumbai, western India. Indian J Malariol 2002;39(3-4):76-82.
43. Johnson A., Leker R., Harun L., et al. Interaction of HLA and age on levels of antibody to Plasmodium falciparum rhoptry-associated proteins 1 and 2. Infect Immun 2000,68(4):2231-6.
44. Meddeb-Garnaoui A., Gritli S., Garbouj S., et al. Association analysis of HLA-class II and class III gene polymorphisms in the susceptibility to Mediterranean visceral leishmaniasis. Hum Immunol 2001;62(5):509-17.
45. Olivo-Díaz A., Debaz H., Alaez C., et al. Role of HLA class II alleles in susceptibility to and protection from localized cutaneous leishmaniasis. Hum Immunol 2004;65:255-61.
46. Peacock C.S., Sanjeevi C.B., Shaw M.A., et al. Genetic analysis of multicase families of visceral leishmaniasis in northeastern Brazil: no major role for class II or class III regions of HLA. Genes Immun 2002;3(6):350-8.
47. Barbier D., Demenais F., Lefait J.F., et al. Susceptibility to human cutaneous leishmaniasis and HLA, Gm, Km markers. Tissue Antigens 1987;30(2):63-7.
48. Lara M., Layrisse Z., Scorza J.V., et al. Immunogenetics of human American cutaneous leishmaniasis- Study of HLA haplotypes in 24 families from Venezuela. Hum Immunol 1991;30:129-35.
49. Morsy T.A., Romia S.A., Al-Ganayni G.A., et al. Histocompatibility antigens (HLA) in Egyptians with two parasitic skin diseases (scabies and leishmaniasis). J Egypt Soc Parasitol 1990;20:565-72.
50. El-Mogy M.H., Abdel-Hamid I.A., Abdel-Razie M.M., et al. Histocompatibility antigens in Egyptians with cutaneous leishmaniasis: a preliminary study. J Dermatol Sci 1993;5(2):89-91.
51. Petzl-Erler M.L., Belich M.P., Queiroz-Telles F. Association of mucosal leishmaniasis with HLA. Hum Immunol 1991;32(4):254-60.
52. Faghiri Z., Tabei S.Z., Taheri F. Study of the association of HLA class II antigens with kala azar. Hum Hered 1995;45:258-61.
53. Singh N., Sundar S., Williams F., et al. Molecular typing of HLA class I and class II antigens in Indian kala-azar patients. Trop Med Int Health 1997;2(5):468-71.
54. Lal S., Bimal S., Sinha A.N., Prasad L.S. Role of HLA-DR antigen on T-cell activation in visceral leishmaniasis. Indian J Exp Biol 1991;29(12):1101-3.
55. De Almeida M.C., Cardoso S.A., Barral-Nieto M. Leishmania chagasi infection alters the expression of cell adhesion and co-stimulatory molecules on human monocyte and macrophage. Int J Parasitol 2003;33(2):153-62.
56. Bacellar O., Russo C., Carvalho E.M. Regulation of T cell response to leishmania antigens by determinants of histocompatibility leukocyte class I and II molecules. Modulation of response to leishmania antigen by HLA class I molecules. Braz J Med Biol Res 1998;31:1575-81.
57. McManus D.P., Ross A.G., Williams G.M., et al. HLA class II antigens positively and negatively associated with hepatosplenic schistosomiasis in a Chinese population. Int J Parasitol 2001;31(7):674-80.
58. Cabello P.H., Krieger H., Lopes J.D., Sant'ana E.J. On the association between HLA-A1 and B5 and clinical forms of schistosomiasis mansoni. Mem Inst. Oswaldo Cruz 1991;86(1):37-40.
59. Salam E.A., Ishaac S., Mahmoud A.A. Histocompatibilty-linked susceptibility for hepatospleenomegaly in human schistosomiasis mansoni. J Immunol 1979;123(4):1829-31.
60. Hafez M., Aboul Hassan S., El-Tahan H., et al. Immunogenetic susceptibility for post-schistosomal hepatic fibrosis. Am J Trop Med Hyg 1991;44(4):424-33.
61. Assaad-Khalil S.H., Helmy M.A., Zaki A., et al. Some genetic, clinical and immunologic interrelations in schistosomiasis mansoni. Ann Biol Clin (Paris) 1993;51(6):619-26.
62. Ohta N., Hayashi M., Tormis L.C., et al. Immunogenetic factors involved in the pathogenesis of distinct clinical manifestations of schistosomiasis japonica in the Philippine population. Trans R Soc Trop Med Hyg 1987;81(2):292-6.
63. Waine G.J., Ross A.G., Williams G.M., et al. HLA class II antigens are associated with resistance or susceptibility to hepatosplenic disease in a Chinese population infected with Schistosoma japonicum. Int J Parasitol 1998;28(4):537-42.
64. Hirayama K., Chen H., Kikuchi M., et al. HLA-DR-DQ alleles and HLA-DP alleles are independently associated with susceptibility to different stages of post-schistosomal hepatic fibrosis in the Chinese population. Tissue Antigens 1999;53(3):269-74.
65. Hirayama K. Immunogenetic analysis of post-schistosomal liver fibrosis. Parasitol Int 2004;53(2):193-6.
66. Dehaide N.H.S., Dantas R.O., Donadi E.A. HLA Class I and II Profiles of Patients Presenting with Chagas' Disease. Dig Dis Sci 1998;43(2):246-52.
67. Cruz-Robles D., Reyes P.A., Monteón-Padilla V.M., et al. MHC Class I and Class II genes in Mexican patients with Chagas' Disease. Hum Immunol 2004;65:60-5.
68. Faé K.C., Drigo S.A., Cunha-Neto E., et al. HLA and b-myosin heavy chain do not influence susceptibility to Chagas' disease cardiomyopathy. Microbes Infect 2000;2:745.51.
69. Layrisse Z., Fernandez M.T., Montagnani S., et al. HLA-C*03 Is a risk factor for cardiomyopathy in Chagas' disease. Hum Immunol 2000; 61:925-9.
70. Fernandez-Mestre M.T., Layrisse Z., Montagnani S., et al. Influence of the HLA class II polymorphism in chronic Chagas' disease. Parasite Immunol 1998 Apr;20(4):197-203.
71. Colorado I.A., Acquatella H., Catalioti F., et al. HLA class II DRB1, DQB1, DPB1 polymorphism and cardiomyopathy due to Trypanosoma cruzi chronic infection. Hum Immunol 2000;61(3):320-5.
72. Fernández-Mestre M.T., Jaraquemada D., Bruno R.E., et al. Analysis of the T-cell receptor b-chain variable-region (V) repertoire in chronic human Chagas' disease. Tissue Antigens 2002;60:10-5.
73. Nieto A., Beraun Y., Collado M.D., et al. HLA haplotypes are associated with differential susceptibility to Trypanosoma cruzi infection. Tissue Antigens 2000;55(3):195-8.
74. Overtvelt L.V., Andrieu M., Verhasselt V., et al. Trypanosoma cruzi down-regulates lipopolysaccharide-induced MHC class I on human dendritic cells and impairs antigen presentation to specific CD8 + T lymphocytes. Int Immunol 2002;14(10):1135-44.
75. Llop E., Rothhammer F., Acuna M., et al. HLA antigens in Chagas cardiomyopathy: new evidence based on a case-control study. Rev Med Chil 1991;119(6):633-6.
76. Benvenuti L.A., Higuchi M.L., Reis M.M. Upregulation of adhesion molecules and class I HLA in the myocardium of chronic chagasic cardiomyopathy and heart allograft rejection, but not in dilated cardiomyopathy. Cardiovasc Pathol 2000;9(2):111-7.
77. Overtvelt L.V., Vanderheyde N., Verhasselt V., et al. Trypanosoma cruzi infects human dendritic cells and prevents their maturation: inhibition of cytokines, HLA-DR, and co-stimulatory molecules. Infect Immun 1999;67(8):4033-40.
78. Souza P.E.A., Rocha M.O.C., Rocha-Vieira E., et al. Monocytes from patients with indeterminate and cardiac forms of Chagas' disease display distinct phenotypic and functional characteristics associated with morbidity. Infect Immun 2004;72(9):5283-91.
79. Polizel J.R., Bueno D., Visentainer J.E., et al. Association of human leukocyte antigen DQ1 and dengue fever in a White Southern Brazilian population. Mem Inst Oswaldo Cruz. 2004;99(6):559-62.
80. Stephens H.A., Klaythong R., Sirikong M., et al. HLA-A and - B allele associations with secondary dengue virus infections correlate with disease severity and the infecting viral serotype in ethnic Thais. Tissue Antigens 2002;60(4):309-18.
81. Loke H., Bethell D.B., Phuong C.X., et al. Strong HLA class I - restricted T cell responses in dengue hemorrhagic fever: a double-edged sword? J Infect Dis 2001;184(11):1369-73.
82. LaFleur C., Granados J., Vargas-Alarcon G., et al. HLA-DR antigen frequencies in Mexican patients with dengue virus infection: HLA-DR4 as a possible genetic resistance factor for dengue hemorrhagic fever. Hum Immunol. 2002;63(11):1039-44.
83. McMichael A., Klenerman P. HIV/AIDS. HLA leaves its footprints on HIV. Science 2002;296(5572):1410-1.
84. Carrington M., O'Brien S.J. The influence of HLA genotype on AIDS. Annu Rev Med 2003;54:535-51.
85. Gao X., Nelson G.W., Karacki P., et al. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med. 2001;344(22):1668-75.
86. Turner D. The human leucocyte antigen (HLA) system. Vox Sanguinis 2004, (Suppl 1):S87-S90.
87. Paranjape R.S. Immunopathogenesis of HIV infection. Indian J Med Res 2005;121(4):240-55.
88. Farquhar C., Rowland-Jones S., Mbori-Ngacha D., et al. Human leukocyte antigen (HLA) B*18 and protection against mother-to-child HIV type 1 transmission. AIDS Res Hum Retroviruses 2004;20(7):692-7.
89. Winchester R., Chen Y., Rose S., et al. Major histocompatibility complex class II DR alleles DRB1*1501 and those encoding HLA-DR13 are preferentially associated with a diminution in maternally transmitted human immunodeficiency virus 1 infection in different ethnic groups: determination by an automated sequence-based typing method. Proc Natl Acad Sci 1995;92:12374-8.
90. Louie L.G., Hartogensis W.E., Jackman R.P., et al. Mycobacterium tuberculosis/HIV-1 coinfection and disease: role of human leukocyte antigen variation. J Infect Dis 2004;189(6):1084-90.
91. Price P., Keane N.M., Stone S.F., et al. MHC haplotypes affect the expression of opportunistic infections in HIV patients. Hum Immunol 2001;62(2):157-64.
92. Diouf K., San A.D., Eisen G., et al. Associations between MHC class I and susceptibility to HIV-2 disease progression. J Hum Virol 2002;5(1):1-7.
93. Bangham C.R. HTLV-1 infections. J Clin Pathol 2000;53(8):581-6.
94. Borducchi D.M., Gerbase-DeLima M., Morgun A., et al. Human leucocyte antigen and human Tell lymphotropic virus type 1 associated diseases in Brazil. Br J Haematol 2003;123(5):954-5.
95. Imirizaldu J.J.Z., Esteban J.C.G., Axpe I.R., et al. Post-transplantation HTLV-1 myelopathy in three recipients from a single donor. J Neurol Neurosurg Psychiatry 2003;74:1080-4.
96. Manns A., Hanchard B., Morgan O.S., et al. Human leukocyte antigen class II alleles associated with human T-cell lymphotropic virus type I infection and adult Tell leukemia/lymphoma in a Black population. J Natl Cancer Inst 1998;90(8):617-22.
97. Jeffery K.J., Usuku K., Hall S.E., et al. HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Proc Natl Acad Sci U S A. 1999;96(7):3848-53.
98. Jeffery K.J., Siddiqui A.A., Bunce M., et al. The influence of HLA class I alleles and heterozygosity on the outcome of human T cell lymphotropic virus type I infection. J Immunol 2000;165(12):7278-84.
99. La Grenade L., Manns A., Fletcher V., et al. Clinical, pathologic, and immunologic features of human T-lymphotrophic virus type I-associated infective dermatitis in children. Arch Dermatol 1998;134(4):439-44.
100. Thio C.L., Thomas D.L., Karacki P., et al. Comprehensive analysis of class I and class II HLA antigens and chronic hepatitis B virus infection. J Virol 2003;77(22):12083-7.
101. Jiang Y.G., Wang Y.M., Liu T.H., Liu J. Association between HLA class II gene and susceptibility or resistance to chronic hepatitis B. World J Gastroenterol 2003;9(10):2221-5.
102. Thursz M.R., Kwiatkowski D., Allsopp C.E., et al. Association between an MHC class II allele and clearance of hepatitis B virus in Gambia. N Engl J Med. 1995;332(16):1065-9.
103. Karan M.A., Tascioglu N.E., Ozturk A.O., et al. The role of HLA antigens in chronic hepatitis B virus infection. J Pak Med Assoc 2002;52(6):253-6.
104. Ahn S.H., Han K.H., Park J.Y., et al. Association between hepatitis B virus infection and HLA-DR type in Korea. Hepatology 2000;31(6):1371-3.
105. Yenigun A., Durupinar B. Decreased frequency of the HLA-DRB1*11 allele in patients with chronic hepatitis C virus infection. J Virol 2002;76(4):1787-9.
106. Thio C.L., Gao X., Goedert J.J., et al. HLA-Cw*04 and hepatitis C virus persistence. J Virol 2002;76(10):4792-7.
107. McKiernan S.M., Hagan R., Curry M., et al. Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source. Hepatology 2004;40(1):108-14.
108. Kryczka W., Brojer E., Kalinska A., et al. DRB1 alleles in relation to severity of liver disease in patients with chronic hepatitis C. Med Sci Monit 2001;Suppl 1:217-20.
109. Thio C.L., Thomas D.L., Goedert J.J., et al. Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis 2001;184(1):16-21.
110. Bosi I., Ancora G., Mantovani W., et al. HLA DR13 and HCV vertical infection. Pediatr Res 2002;51(6):746-9.
111. Yee L.J. Host genetic determinants in hepatitis C virus infection. Genes Immun 2004;5(4):237-45.